OncoTherapy Science Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	Mar '20 Mar 31, 2020	2015 - 2019
Net Income	-	-1,285	-1,116	-2,570	-1,560	-2,236	Upgrade
Depreciation & Amortization	-	-	-	16	49	39	Upgrade
Loss (Gain) From Sale of Assets	-	154	21	547	10	115	Upgrade
Other Operating Activities	-	-2	-17	-3	-3	-2	Upgrade
Change in Accounts Receivable	-	87	276	-247	-123	-12	Upgrade
Change in Inventory	-	25	131	-189	-16	-	Upgrade
Change in Accounts Payable	-	-158	-240	385	-39	-128	Upgrade
Change in Other Net Operating Assets	-	-48	151	-12	-80	-51	Upgrade
Operating Cash Flow	-	-1,227	-794	-2,073	-1,762	-2,275	Upgrade
Capital Expenditures	-	-2	-4	-456	-43	-130	Upgrade
Sale of Property, Plant & Equipment	-	-	-	-	-	102	Upgrade
Other Investing Activities	-	-31	-16	-11	-9	-2	Upgrade
Investing Cash Flow	-	-33	-20	-467	-52	-30	Upgrade
Issuance of Common Stock	-	676	-	1,478	-	2,164	Upgrade
Other Financing Activities	-	-5	95	-	-	-	Upgrade
Financing Cash Flow	-	671	95	1,478	-	2,164	Upgrade
Foreign Exchange Rate Adjustments	-	-	-	-	-	-1	Upgrade
Miscellaneous Cash Flow Adjustments	-	-	-	-	-	-1	Upgrade
Net Cash Flow	-	-589	-719	-1,062	-1,814	-143	Upgrade
Free Cash Flow	-	-1,229	-798	-2,529	-1,805	-2,405	Upgrade
Free Cash Flow Margin	-	-201.47%	-70.37%	-219.34%	-543.67%	-761.08%	Upgrade
Free Cash Flow Per Share	-	-5.78	-4.14	-13.49	-10.24	-14.75	Upgrade
Cash Income Tax Paid	-	2	2	2	2	2	Upgrade
Levered Free Cash Flow	-	-937	-231.88	-1,782	-1,196	-1,551	Upgrade
Unlevered Free Cash Flow	-	-937	-231.88	-1,782	-1,196	-1,551	Upgrade
Change in Net Working Capital	-110	235	-464	59	178	92	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.